Skip to content

Cognitive-Motor Training for Gait Adaptability in Parkinson Disease

Cognitive-Motor Training on Cognitive Function and Gait Adaptability in People With Parkinson's Disease

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07907718
Enrollment
50
Registered
2026-10-30
Start date
2026-11-01
Completion date
2029-08-31
Last updated
2026-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Cognitive-motor training, Gait adaptability, Executive function, Electroencephalography

Brief summary

Cognitive-motor training combines thinking tasks with physical movements, encouraging participants to choose appropriate actions and adjust their movements according to different task demands. Training that involves stopping or changing a movement may help people with Parkinson's disease respond to changing situations. These abilities may also support walking in challenging environments, such as stepping over obstacles. However, the effects of this type of training on cognitive function, walking performance, and brain activity remain unclear. Therefore, this study aims to compare the effects of cognitive-motor co-dependent training with conventional exercise training on these outcomes in people with Parkinson's disease.

Interventions

Cognitive-motor training is that cognitive tasks incorporated into motor tasks.

OTHERConventional physiotherapy

Conventional physiotherapy includes ROM exercise, stretching, strengthening exercise, and eye-hand coordination.

Sponsors

National Yang Ming Chiao Tung University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* A clinical diagnosis of idiopathic Parkinson's disease * Stable use of prescribed antiparkinsonian medication for at least two weeks * Modified Hoehn and Yahr stage I to III * Age between 18 and 80 years * Ability to ambulate independently for at least 30 meters without assistive devices * A Mini-Mental State Examination (MMSE) score of ≥ 24 * Corrected vision and hearing sufficient to effectively receive external stimuli

Exclusion criteria

* The presence of any neurological, musculoskeletal, or cardiovascular disorders that could affect participation in this study * The presence of psychiatric disorders that could interfere with the ability to follow instructions or comply with study procedures * A history of brain surgery, such as deep brain stimulation (DBS)

Design outcomes

Primary

MeasureTime frameDescription
Gait speedBefore and after 8 weeks of intervention, as well as 4 weeks after interventionGait speed during obstacle crossing was measured using the GAITRite system. Continuous obstacle-crossing walking performance was assessed using the GaitUp system.
Step lengthBefore and after 8 weeks of intervention, as well as 4 weeks after interventionUsing GAITRite system to measure step length
Step widthBefore and after 8 weeks of intervention, as well as 4 weeks after interventionUsing GAITRite system to measure step width
Single support timeBefore and after 8 weeks of intervention, as well as 4 weeks after interventionUsing GAITRite system to measure single support time
Gait VariabilityBefore and after 8 weeks of intervention, as well as 4 weeks after interventionGait variability during continuous obstacle crossing will be assessed using the GaitUp system and expressed as the coefficient of variation (CV = standard deviation / mean × 100%) of step time and stride length.
Stride lengthBefore and after 8 weeks of intervention, as well as 4 weeks after interventionUsing the GaitUp system to measure stride length during continuous obstacle-crossing walking.
Swing phaseBefore and after 8 weeks of intervention, as well as 4 weeks after interventionUsing the GaitUp system to measure swing phase during continuous obstacle-crossing walking.
Four Square Step TestBefore and after 8 weeks of intervention, as well as 4 weeks after interventionThe Four Square Step Test is a test used to assess the ability to step over objects and measures the time in seconds to navigate all four squares.
Event-related potential - N2Before and after 8 weeks of intervention, as well as 4 weeks after interventionMeasure event-related potential through electroencephalography during the Go/No-go test
Event-related potential - P300Before and after 8 weeks of intervention, as well as 4 weeks after interventionMeasure event-related potential through electroencephalography during the Go/No-go test
Stroop color and word testBefore and after 8 weeks of intervention, as well as 4 weeks after interventionRecord numbers of corrected color words which the subject responds within 45 sec.
Trail making testBefore and after 8 weeks of intervention, as well as 4 weeks after interventionTrail making test contain part A and part B. Faster completing the test indicates better executive function.

Secondary

MeasureTime frameDescription
Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS)Before and after 8 weeks of intervention, as well as 4 weeks after interventionMotor symptoms will be assessed using Part III of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS). Scores range from 0 to 132, with higher scores indicating greater motor impairment.
Single-Leg Standing BalanceBefore and after 8 weeks of intervention, as well as 4 weeks after interventionBalance will be assessed by measuring the time, in seconds, that participants can stand on one leg. Longer standing times indicate better balance.
Montreal Cognitive AssessmentBefore and after 8 weeks of intervention, as well as 4 weeks after interventionMontreal Cognitive Assessment ranges from 0 to 30. Higher scores reflect better cognitive performances.

Countries

Taiwan

Contacts

CONTACTYea-Ru Yang, PhD
yryang@nycu.edu.tw+886228267279

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Oct 31, 2026